CA-INGRAM-MICRO
4.5.2021 14:05:12 CEST | Business Wire | Press release
Growing its Artificial Intelligence (AI) portfolio, Ingram Micro Inc. today announced an expanded, and now global, business relationship with UiPath , a leading enterprise automation software company and Robotic Process Automation (RPA) tech innovator.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005476/en/
RPA enables organizations in the digital transformation (DX) era to increase efficiency, workflow determinism, operation accuracy and compliance with regulations by automating repetitive and time-consuming mundane tasks. Additionally, software robots work to establish end-to-end automation across the organization while driving costs down. Ingram Micro’s broad and specialized Advanced Solutions portfolio began offering AI and RPA solutions a few years ago and has become one of the organization’s fastest-growing global practices.
“Robotic process automation is an important component within a company’s digital transformation game plan, and a great sales wedge for channel partners to introduce DX solutions and services into their existing end user customer base,” said Sabine Howest, vice president, global partner engagement and IoT, Ingram Micro Inc. “Using AI to automate repeatable, rules-driven processes is a practice companies of all sizes can benefit from and a growth opportunity we’re ready to drive with UiPath through our growing and global Advanced Solutions organization.”
“We’re thrilled that UiPath is offering additional support to high-value service providers like us through its new Ingram Micro program,” said Bhavyesh Virani, co-CEO of WonderBotz, a UiPath partner. “Ingram Micro’s global reach will help WonderBotz capture the rising demand for our custom services as well as for our prebuilt turnkey solutions for F&A professionals and healthcare, finance, banking, and hospitality leaders. The new UiPath/Ingram Micro program is an all-around win, enabling us to spend more time on delivering industry-leading client services.”
Ingram Micro’s relationship with UiPath started in India in 2018 and was quickly followed by China. Currently, the relationship is now expanded to North America and Latin America as well as Europe, Middle East, Africa, and the remainder of Asia Pacific. The team at Ingram Micro maintains a mature and dedicated UiPath team of experts who are here to help channel partners throughout the sales cycle including opportunity identification, design thinking, advisory services, licensing and training. With the support of Ingram Micro’s Centers of Excellence, channel partners selling UiPath benefit from shared best practices, “follow the sun” support services and global resources designed to meet the varied demands of the market locally, regionally, and globally.
“Ingram Micro and UiPath are partner-first organizations equally committed to continually investing in our partners to drive greater service differentiation, exceptional growth, and improved profitability,” says Thomas Hansen, Chief Revenue Officer, UiPath. “Enterprise automation is a category channel partners cannot ignore, and an investment enterprise organizations are making because of the immediate and measurable return on investment and improvement to the associate experience and the customer experience. We are thrilled to expand our successful relationship with Ingram Micro worldwide and look forward to helping channel partners capitalize on the market potential for RPA.”
In Q1 2021, the Forrester Wave™*: Robotic Process Automation named UiPath “a Leader” with the highest ranking in each of three categories: Current Offering, Strategy, and Market Presence. Additionally, UiPath Vice President of Global Alliances and Partners, Cheryln Chin, and Senior Vice President of Operations and Partners, Eddie O’Brien were recently named to the 2021 CRN Channel Chiefs list, along with eight Ingram Micro channel executives.
The entire UiPath portfolio is now available to Ingram Micro channel partners worldwide. To learn more about UiPath, contact your Ingram Micro partner manager. For Quote to order support, please email: UiPath-licensing@ingrammicro.com and for sales and pre-sales support, please email: UiPath-sd@ingrammicro.com .
*The Forrester Wave™: Robotic Process Automation, Q1 2021, March 15, 2021
About UiPath
UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005476/en/
Link:
Social Media:
https://www.facebook.com/IngramMicroLatinAmericaDivision
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom